Merck unveils $3 billion cost cutting plan
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Revenue increased 11.4 per cent to Rs. 8,545 crore
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
Subscribe To Our Newsletter & Stay Updated